GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CanBas Co Ltd (TSE:4575) » Definitions » FCF Margin %

CanBas Co (TSE:4575) FCF Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is CanBas Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CanBas Co's Free Cash Flow for the three months ended in Dec. 2023 was 円0.00 Mil. CanBas Co's Revenue for the three months ended in Dec. 2023 was 円0.00 Mil. Therefore, CanBas Co's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, CanBas Co's current FCF Yield % is -15.62%.

The historical rank and industry rank for CanBas Co's FCF Margin % or its related term are showing as below:


During the past 13 years, the highest FCF Margin % of CanBas Co was -285.30%. The lowest was -632.04%. And the median was -409.19%.

TSE:4575's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -146.375
* Ranked among companies with meaningful FCF Margin % only.


CanBas Co FCF Margin % Historical Data

The historical data trend for CanBas Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanBas Co FCF Margin % Chart

CanBas Co Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -332.04 -502.66 -632.04 - -

CanBas Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CanBas Co's FCF Margin %

For the Biotechnology subindustry, CanBas Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanBas Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CanBas Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where CanBas Co's FCF Margin % falls into.



CanBas Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

CanBas Co's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-1398.936/0
= %

CanBas Co's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CanBas Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of CanBas Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CanBas Co (TSE:4575) Business Description

Traded in Other Exchanges
N/A
Address
9 Toriyoko-cho, Shizuoka, JPN, 410-0891
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.

CanBas Co (TSE:4575) Headlines

No Headlines